The EPS projection of Epizyme, Inc. (NASDAQ:EPZM) for quarter ended 2016-09-30 is $-0.55. Last week, the EPS forecast was $-0.55 against target of $-0.55, a month earlier. Two months ago, this estimate was $-0.55 versus forecast of $-0.55 three months earlier, implying a deviation of 0%.
Epizyme, Inc. (NASDAQ:EPZM) stated that 18 days ago, its stock price was positively revised 2 times while negative revisions were 0.
In last week, the experts lowered EPS 0 times and increased EPS 0 times. In last 30, 120, 60 and 90 days, the experts upped revisions 0 , 2, 2, and 2, correspondingly.
EPS estimate downgrade for Epizyme, Inc. (NASDAQ:EPZM) in the preceding 30, 120, 60 and 90 days were 0, 0, 1, and 1, correspondingly.
Epizyme, Inc. (NASDAQ:EPZM) EPS target for the quarter closed 1 was $-0.55, based on 4 recommendations. As reported on 2016-05-09 the EPS was $-0.41. The change was $0.07, implying a percentage deviation of 14.58%. The projections showed a standard deviation of 0.05.
Quarterly Sales Estimates
Epizyme, Inc. (NASDAQ:EPZM) yearly sales prediction for the fiscal 2016 stands at $0.648 and the median estimate is at $0.5. Almost 4 analysts issued sales target.
Highest sales target is $1.12 while the lowest target is $0.472 showing standard deviation of 0.314%.
As many as 4 analysts have sales targets revised upside while 4 reduced sales estimates, implying a deviation of 0%.
Last month, 4 revised sales number projection on upside while 4 lowered the sales projections, implying a deviation of 0%.
A quarter ago, 4 hiked sales target and 4 reduced sales forecast. Epizyme, Inc. (NASDAQ:EPZM) announced that the deviation in forecast was -23.674%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...